Favipiravir, an antiviral for COVID-19?
作者信息
Coomes Eric A, Haghbayan Hourmazd
机构信息
Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Division of Cardiology, London Health Sciences Centre, Western University, London, Ontario, Canada.
出版信息
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
Abstract
摘要
相似文献
1
Favipiravir, an antiviral for COVID-19?
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
2
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
Heredity (Edinb). 2020 May;124(5):619-620. doi: 10.1038/s41437-020-0314-z. Epub 2020 Apr 6.
3
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
4
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Virol J. 2020 Sep 24;17(1):141. doi: 10.1186/s12985-020-01412-z.
5
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
6
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Oct 13;21(1):847. doi: 10.1186/s13063-020-04766-5.
7
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Mymensingh Med J. 2020 Jul;29(3):747-754.
8
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Jun 5;21(1):488. doi: 10.1186/s13063-020-04430-y.
9
A Favipiravir-induced Fever in a Patient with COVID-19.
Intern Med. 2020;59(22):2951-2953. doi: 10.2169/internalmedicine.5394-20. Epub 2020 Nov 15.
10
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
Intern Med. 2020 Sep 15;59(18):2327-2329. doi: 10.2169/internalmedicine.5377-20. Epub 2020 Jul 28.
引用本文的文献
1
Organ-specific effects of curcumin on favipiravir-induced oxidative stress: renal benefit and hepatic risk.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 21. doi: 10.1007/s00210-025-04458-4.
2
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.
Daru. 2024 Dec;32(2):801-823. doi: 10.1007/s40199-024-00524-z. Epub 2024 Jul 19.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
BMC Infect Dis. 2024 Jan 15;24(1):89. doi: 10.1186/s12879-023-08835-3.
5
Electroanalytical investigation and voltammetric quantification of antiviral drug favipiravir in the pharmaceutical formulation and urine sample using a glassy carbon electrode in anionic surfactant media.
Turk J Chem. 2022 Feb 23;46(3):869-880. doi: 10.55730/1300-0527.3375. eCollection 2022.
6
The COVID-19, tuberculosis and HIV/AIDS: Ménage à Trois.
Front Immunol. 2023 Jan 27;14:1104828. doi: 10.3389/fimmu.2023.1104828. eCollection 2023.
7
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.
Eur J Med Chem Rep. 2021 Dec;3:100013. doi: 10.1016/j.ejmcr.2021.100013. Epub 2021 Oct 22.
8
Structural Elucidation of Alkali Degradation Impurities of Favipiravir from the Oral Suspension: UPLC-TQ-ESI-MS/MS and NMR.
Molecules. 2022 Aug 31;27(17):5606. doi: 10.3390/molecules27175606.
9
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.
J Biomed Sci. 2022 Sep 6;29(1):65. doi: 10.1186/s12929-022-00847-6.
10
Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats.
Microchem J. 2022 Oct;181:107769. doi: 10.1016/j.microc.2022.107769. Epub 2022 Jul 15.
本文引用的文献
1
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
2
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.
Pharmacol Ther. 2020 May;209:107512. doi: 10.1016/j.pharmthera.2020.107512. Epub 2020 Feb 22.
3
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
4
A novel coronavirus outbreak of global health concern.
Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24.
5
Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014.
Clin Infect Dis. 2016 Nov 15;63(10):1288-1294. doi: 10.1093/cid/ciw571. Epub 2016 Aug 23.
6
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar.
7
Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers.
Lancet Infect Dis. 2015 Nov;15(11):1300-4. doi: 10.1016/S1473-3099(15)00228-5. Epub 2015 Aug 25.
8
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
Antiviral Res. 2014 May;105:17-21. doi: 10.1016/j.antiviral.2014.02.014. Epub 2014 Feb 26.
9
Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.
Antiviral Res. 2014 Apr;104:153-5. doi: 10.1016/j.antiviral.2014.01.012. Epub 2014 Jan 24.
10
Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29.
Zotero 插件